24 March 2014 Nanocapsules of perfluorooctyl bromide for theranostics: from formulation to targeting
Author Affiliations +
The need to detect cancer at its early stages, as well as, to deliver chemotherapy to targeted site motivates many researchers to build theranostic platforms which combine diagnostic and therapy. Among imaging modalities, ultrasonography and Magnetic Resonance Imaging (MRI) are widely available, non invasive and complement each other. Both techniques often require the use of contrast agents. We have developed nanocapsules of perfluorooctyl bromide as dual contrast agent for both imaging modalities. The soft, amorphous polymer shell provides echogenicity, while the high-density perfluorinated liquid core allows detection by 19F MRI. We have used a shell of poly(lactide-co-glycolide) (PLGA) since this polymer is biodegradable, biocompatible and can be loaded with drugs. These capsules were shown to be efficient in vitro as contrast agents for both 19F MRI and ultrasonography. In addition, for in vivo applications a poly(ethyleneglycol) (PEG) coating promotes stability and prolonged circulation. Being stealth, nanocapsule can accumulate passively into implanted tumors by the EPR effect. We will present nanocapsule formulation and characterization, and will show promising in vivo results obtained for both ultrasonography and 19F MRI.
© (2014) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
O. Diou, O. Diou, E. Fattal, E. Fattal, T. Payen, T. Payen, S. L. Bridal, S. L. Bridal, J. Valette, J. Valette, N. Tsapis, N. Tsapis, "Nanocapsules of perfluorooctyl bromide for theranostics: from formulation to targeting", Proc. SPIE 8955, Colloidal Nanoparticles for Biomedical Applications IX, 895514 (24 March 2014); doi: 10.1117/12.2037162; https://doi.org/10.1117/12.2037162

Back to Top